drugset
drugset / Trial / NCT05503953

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

NCT05503953 ↗

Phase 3 Completed 318 enrolled Ahn-Gook Pharmaceuticals Co.,Ltd Daehwa Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS

Timeline

Start
2022-10-18
Primary completion
2025-06-10
Completion
2026-06-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator AGLS Unknown — —
Subject AGSAVI Unknown — —

Indications

essential hypertension